Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review

Clinical Therapeutics

Volumn 29, Issue 11, 2007, Pages 2433-2439

  Lorente, Leonardo ^a   Jiménez, Alejandro ^a   Palmero, Salome ^a   Jiménez, Juan José ^a   Iribarren, José Luís ^a   Santana, Melitón ^a   Martín, María M ^a   Mora, Maria L ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

ceftazidime; continuous infusion; gram negative bacteria; intermittent infusion; ventilator associated pneumonia

Indexed keywords

CEFTAZIDIME; TOBRAMYCIN;

ADULT; AGE; APACHE; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DATA EXTRACTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; RISK; SEPSIS RELATED ORGAN FAILURE ASSESSMENT; SEX; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; APACHE; CEFTAZIDIME; CEPHALOSPORINS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 37349091127     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.11.003     Document Type: Article

References (42)

1. Leu H., Kaiser D., Mori M., et al. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol 129 (1989) 1258-1267
2. Heyland D., Cook D., Griffith L., et al., for the Canadian Critical Trials Group. The attributable morbidity and mortality of ventilator associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 159 (1999) 1249-1256
3. Bercault N., and Boulain N. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: A prospective case-control study. Crit Care Med 29 (2001) 2303-2309
4. Craig C., and Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of-stay and mortality. Am J Infect Control 12 (1984) 233-238
5. Hanberger H., Garcia-Rodriguez J., Gobernado M., et al., for the French and Portuguese ICU Study Groups. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 281 (1999) 67-71
6. Drusano G. Role ofpharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 32 (1988) 289-297
7. Vogelrnan B., Gudrnundsson S., Leggett J., et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158 (1988) 831-847
8. Ebert S., and Craig W. Pharmacodynamic properties of-an- tibiotics: Application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 11 (1990) 319-326
9. Craig W., and Ebert S. Continuous infusion ofbeta-lactam an- tibiotics. Antimicrob Agents Chemother 36 (1992) 2577-2583
10. Onyeji C., Nicolau D., Nightingale C., and Quintiliani R. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob Agents Chemother 38 (1994) 1112-1117
11. Craig W. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 14 (1995) 636-642
12. Mouton J., and den Hollander J. Killing of Pseudomonas aerugmosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38 (1994) 931-936
13. Nicolau D., Nightingale C., Banevicius M., et al. Serum bactericidal activity of ceftazidime: Continuous versus intermittent injections. Antimicrob Agents Chemother 40 (1996) 61-64
14. Robaux M., Dube L., Caillon J., et al. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aerugmosa rabbit endocarditis model. J Antimicrob Chemother 47 (2001) 617-622
15. Roosendaal R., Bakker-Woudenberg I., van den Berg J., and Michel M. Therapeutic efficacy of continuous versus intermittent administration ofceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 152 (1985) 373-378
16. Lemmen S., Engels I., and Daschner F. Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aerugmosa in healthy volunteers. J Antimicrob Chemother 39 (1997) 841-842
17. Angus B., Smith M., Suputtamongkol Y., et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 50 (2000) 184-191
18. Benko A., Cappelletty D., Kruse J., and Rybak M. Continuous infusion vs intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Ckemotker 40 (1996) 691-695
19. Buijk S., Gyssens I., Mouton J., et al. Pharmacokinetics of ceffazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Ckemotker 49 (2002) 121-128
20. Lipman J., Gomersall C., Gin T., et al. Continuous infusion ceftazidime in intensive care: A randomized controlled trial. J Antimicrob Ckemotker 43 (1999) 309-311
21. Nicolau D., McNabb J., Lacy M., et al. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumo- nia. Clin Drug Invest 18 (1999) 133-139
22. Cousson J., Floch T., Vernet-Garnier V., et al. Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia [in French]. Patkol Biol (Paris,) 53 (2005) 546-550
23. Alou L., Aguilar L., Sevillano D., et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aerugmosa? An in vitro pharmacodynamic model. J Antimicrob Ckemotker 55 (2005) 209-213
24. Girardi C., Tonnellier M., Goldstein I., et al., for the Experimental ICU Study Group. Lung deposition of continu- ous and intermittent intravenous ceftazidime in experimental Pseudomonas aerugmosa bronchopneumonia. Intensive Care Med 32 (2006) 2042-2048
25. Daenen S., and de Vries-Hospers H. Cure of Pseudomonas aerugmosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet 1 (1988) 937 Letter
26. Vinks A., Brimicombe R., Heijerman H., and Bakker W. Continuous infusion of ceffazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology and pharmacokinetics. J Antimicrob Ckemotker 40 (1997) 125-133
27. Hanes S., Wood G., Herring V., et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 179 (2000) 436-440
28. McNabb J., Nightingale C., Quintiliani R., and Nicolau D. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 21 (2001) 549-555
29. Laghzaoui F., Murcia J., Llorens P., and Portilla J. Continuous ceftazidime infusion in the treatment of Pseudomonas aeruginosa infections in a Hospital at Home Unit [in Spanish]. Enferm Infecc Microbiol Clin 25 (2007) 71-72 Letter
30. Cockcroft D., and Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
31. Vincent J., Moreno R., Takala J., et al., for the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine. The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. Intensive Care Med 22 (1996) 707-710
32. Walker S., and Dranitsaris G. Ceffazidime stability in normal saline and dextrose in water. Can J Hosp Pkarm 41 (1988) 65-66
33. Viaene E., Chanteux H., Servais H., et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46 (2002) 2327-2332
34. Zhou M., and Notari R. Influence of pH, temperature, and buffers on the kinetics of ceffazidime degradation in aqueous solutions. J Pharm Sci 84 (1995) 534-538
35. Gupta V., Bethea C., and de la Torre M. Chemical stabilities of cefoperazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections. J Clin Pkarm Ther 13 (1988) 199-205
36. Nicolau D., Freeman C., Belliveau P., et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Ckemotker 39 (1995) 650-655
37. Simon G. Alternative analyses forthe singly-ordered contingency table. J Am Star Assoc 69 (1974) 971-976
38. Mehta C., and Patel N. Singly ordered RX C contingency tables. In: Mehta C., and Patel N. (Eds). StatXact 5 (2001), Cytel Software Co, Cambridge, Mass 765-785
39. Hosmer D., and Lemeshow S. Assessing interaction and confounding. Applied Logistic Regression (1989), John Wiley & Sons, New York, NY 63-68
40. Kleinbaum D. Modeling strategy for assessing interaction and confounding. Logistic Regression. A Self Learning Text (1994), Springer, New York, NY 192-221
41. Lang T., and Secic M. Analyzing multiple variables. How to Report Statistics in Medicine (1997), American College of Physicians, Philadelphia, Pa 127-135
42. Lorente L., Lorenzo L., Martin M., et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pkarmacotker 40 (2006) 219-223